ARVN insider buying and SEC filings, explained
Arvinas, Inc. · CIK 1655759
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Company profile
- Exchanges
- Nasdaq
- Industry (SIC)
- Pharmaceutical Preparations
- State of incorporation
- DE
- Fiscal year end
- Dec 31
- Former names
- ARVINAS INC.; ARVINAS HOLDING COMPANY, LLC
Insider activity in the last 12 months
Bought
$268K
Insiders who bought
1
Sold (not marked 10b5-1)
$1.4M
Planned sales (10b5-1)
$66K
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Jun 24, 2026 | Planned (10b5-1) | Andrew Saik (CFO) sold 5,696 shares at $8.16 ($46K), marked as a 10b5-1 plan trade. Holdings down 3% to 187,432 shares. | SEC filing Filed Jun 24, 2026 |
| Jun 17, 2026 | Planned (10b5-1) | Angela M Cacace (Chief Scientific Officer) sold 2,576 shares at $7.60 ($20K), marked as a 10b5-1 plan trade. Holdings down 1% to 180,390 shares. | SEC filing Filed Jun 18, 2026 |
| May 21, 2026 | Sale | Randy Teel (CEO and Director) sold 2,209 shares at $9.04 ($20K). Holdings down 1% to 285,009 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 22, 2026 |
| May 11, 2026 | Sale | Andrew Saik (CFO) sold 11,139 shares at $9.94 ($111K). Holdings down 5% to 193,128 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 13, 2026 |
| May 11, 2026 | Sale | David K Loomis (VP, Chief Accounting Officer) sold 1,919 shares at $9.94 ($19K). Holdings down 5% to 40,193 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 13, 2026 |
| May 11, 2026 | Sale | Angela M Cacace (Chief Scientific Officer) sold 9,657 shares at $9.94 ($96K). Holdings down 5% to 182,966 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 13, 2026 |
| May 11, 2026 | Sale | Noah Berkowitz (Chief Medical Officer) sold 11,108 shares at $9.94 ($110K). Holdings down 5% to 191,395 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 13, 2026 |
| May 11, 2026 | Sale | Randy Teel (CEO and Director) sold 9,657 shares at $9.94 ($96K). Holdings down 3% to 287,218 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 13, 2026 |
| Mar 18, 2026 | Sale | Noah Berkowitz (Chief Medical Officer) sold 6,435 shares at $11.10 ($71K). Holdings down 3% to 202,503 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 19, 2026 |
| Mar 6, 2026 | Purchase (code P) | Briggs Morrison (Director) bought 20,000 shares at about $13.40 ($268K), reported as a purchase (code P). Holdings up 26% to 96,021 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 9, 2026 |
| Feb 27, 2026 | Sale | John G Houston (Director) sold 35,297 shares at about $13.21 ($466K). Holdings down 3% to 1,122,183 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 2, 2026 |
| Feb 23, 2026 | Sale | David K Loomis (Chief Accounting Officer) sold 1,108 shares at $12.16 ($13K). Holdings down 4% to 29,692 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 25, 2026 |
| Feb 23, 2026 | Sale | Angela M Cacace (Chief Scientific Officer) sold 3,609 shares at $12.16 ($44K). Holdings down 2% to 147,623 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 25, 2026 |
| Feb 23, 2026 | Sale | Randy Teel (CEO and Director) sold 4,786 shares at $12.16 ($58K). Holdings down 3% to 149,696 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 25, 2026 |
| Feb 13, 2026 | Sale | Randy Teel (CEO and Director) sold 4,403 shares at $11.89 ($52K). Holdings down 3% to 154,482 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 18, 2026 |
| Feb 13, 2026 | Sale | Andrew Saik (CFO) sold 5,134 shares at $11.89 ($61K). Holdings down 3% to 159,267 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 18, 2026 |
| Feb 13, 2026 | Sale | Angela M Cacace (Chief Scientific Officer) sold 4,592 shares at $11.89 ($55K). Holdings down 3% to 151,232 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 18, 2026 |
| Feb 13, 2026 | Sale | Noah Berkowitz (Chief Medical Officer) sold 5,685 shares at $11.89 ($68K). Holdings down 3% to 163,938 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 18, 2026 |
| Feb 13, 2026 | Sale | David K Loomis (Chief Accounting Officer) sold 1,016 shares at $11.89 ($12K). Holdings down 3% to 30,800 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 18, 2026 |
| Nov 7, 2025 | Sale | David K Loomis (Chief Accounting Officer) sold 230 shares at $9.89 ($2K). Holdings down 1% to 31,697 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 7, 2025 |
11 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
| Filed | Items | Tag | Source |
|---|---|---|---|
| Nov 3, 2026, 8:09 AM ET 8-K | Earnings released (Item 2.02) Reg FD disclosure (Item 7.01) | SEC filing |
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow ARVN in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.